ImmuCell(US:ICCC)2025-10-07 20:06FORM 8-K Filing Details This section details the foundational information of the Form 8-K filing, including registrant identity and securities specifics General Information This section provides foundational details of the Form 8-K filing, including registrant identity, jurisdiction, and securities information - The report is a Current Report on Form 8-K, filed under Section 13 or 15(d) of The Securities Exchange Act of 19342 Registrant and Filing Details | Detail | Value | | :--- | :--- | | Registrant Name | ImmuCell Corporation | | Date of Report | October 7, 2025 | | State of Incorporation | Delaware | | Commission File Number | 001-12934 | | IRS Employer Identification No. | 01-0382980 | | Registrant's Telephone Number | 207-878-2770 | | Title of Class | Common Stock, $0.10 par value per share | | Trading Symbol | ICCC | | Exchange Registered On | The Nasdaq Capital Market | - The registrant is not an emerging growth company and has not elected the extended transition period for new accounting standards4 Reported Events This section details the specific events reported in the Form 8-K, including financial results and required exhibits Item 2.02. Results of Operations and Financial Condition ImmuCell Corporation announced preliminary, unaudited product sales for Q3 2025 via press release, furnished but not filed for liability - ImmuCell Corporation issued a press release on October 7, 2025, announcing preliminary, unaudited product sales for the quarter ended September 30, 20255 - The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K5 - Information under Item 2.02 is furnished, not filed, limiting liability under Section 18 of the Securities Exchange Act of 19346 Item 9.01. Financial Statements and Exhibits This section lists exhibits furnished with the Form 8-K filing, including the press release and interactive data file Exhibits Furnished | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release of the Company dated October 7, 2025 | | 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) | - Exhibits related to Item 2.02 are furnished, not filed7 Signatures and Exhibit Index This section includes the official signatures for the report and a comprehensive index of all attached exhibits SIGNATURE The report is duly signed by authorized officers of ImmuCell Corporation, affirming compliance with Exchange Act requirements - The report was signed on October 7, 2025, by Michael F. Brigham (President, CEO, PFO) and Timothy C. Fiori (CFO)91011 Exhibit Index This section provides a final, consolidated list of all exhibits included in the Form 8-K filing for easy reference Consolidated Exhibit List | Exhibit No. | Description | | :--- | :--- | | 99.1 | Press Release of the Company dated October 7, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |